Daniel H. Ahn, DO, discusses the evolution of targetable alterations in colorectal cancer.
Daniel H. Ahn, DO, an oncologist, internist, and assistant professor of medicine at Mayo Clinic, discusses the evolution of targetable alterations in colorectal cancer (CRC).
Historically, KRAS G12D, which was used as a predictive biomarker for anti-EGFR monoclonal antibodies, was one of the only targetable alterations in CRC, says Ahn.
However, several additional driver mutations, including BRAF V600E mutations, microsatellite instability–high status, and NTRK fusions, have been discovered, Ahn says. Additionally, MET, FGFR, and BRAF non-V600E mutations are currently under exploration as potential actionable alterations.
Currently, the majority of patients with CRC will benefit from targeted therapy, whereas approximately 50% to 60% of patients derived benefit from targeted therapy in the past, Ahn explains.
The role of targeted therapy continues to advance the CRC armamentarium, and, as such, the use of comprehensive next-generation sequencing panels is critical to ensure patients undergo the optimal course of therapy, Ahn concludes.